Jul 25
|
BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025
|
Jul 16
|
BriaCell Therapeutics Announces Closing of $15 million Public Offering
|
Jul 15
|
BriaCell Therapeutics Announces Pricing of $15 million Public Offering
|
Jul 15
|
BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer
|
Jul 11
|
BriaCell’s Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer
|
Jul 10
|
BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient
|
Jun 25
|
Here's Why We're A Bit Worried About BriaCell Therapeutics' (TSE:BCT) Cash Burn Situation
|
Jun 24
|
BriaCell Up in U.S. Pre-market, as Data Safety Board Review Recommends Phase 3 Study Continues
|
Jun 24
|
BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer
|
Apr 10
|
BriaCell's Subsidiary, BriaPro, Develops Novel Antibodies to Anti-Cancer Target B7-H3
|
Feb 11
|
BRIACELL THERAP (BCTX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
|
Jan 3
|
BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025
|
Jan 3
|
BriaCell Announces Proposed Effective Date of Share Consolidation
|
May 15
|
BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering
|
Apr 24
|
BriaCell Announces Oral and Poster Presentations at ASCO 2024
|
Apr 10
|
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer
|
Apr 9
|
BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR
|
Mar 7
|
BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies
|
Mar 6
|
BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference
|
Feb 27
|
BriaCell Provides Update on Alleged Illegal Trading of Public Securities
|